Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTRUST-AF PCI
NL-OMON46857Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Started Nov 2017; status: active, not recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON46857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46857.